Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor.
about
N-arachidonoyl glycine, an abundant endogenous lipid, potently drives directed cellular migration through GPR18, the putative abnormal cannabidiol receptorsiRNA knockdown of GPR18 receptors in BV-2 microglia attenuates N-arachidonoyl glycine-induced cell migrationN-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory propertiesThe elmiric acids: biologically active anandamide analogsOrphan endogenous lipids and orphan GPCRs: a good matchA biosynthetic pathway for anandamideThe cannabinoid acids, analogs and endogenous counterpartsN-Acyl amines of docosahexaenoic acid and other n-3 polyunsatured fatty acids - from fishy endocannabinoids to potential leadsThe endocannabinoid anandamide is a precursor for the signaling lipid N-arachidonoyl glycine by two distinct pathwaysActions of N-arachidonyl-glycine in a rat inflammatory pain modelThe endocannabinoid/endovanilloid N-arachidonoyl dopamine (NADA) and synthetic cannabinoid WIN55,212-2 abate the inflammatory activation of human endothelial cellsΔ(9) -Tetrahydrocannabinol and N-arachidonyl glycine are full agonists at GPR18 receptors and induce migration in human endometrial HEC-1B cellsPalmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cellsCharacterization of palmitoylethanolamide transport in mouse Neuro-2a neuroblastoma and rat RBL-2H3 basophilic leukaemia cells: comparison with anandamideCharacterization of non-olfactory GPCRs in human sperm with a focus on GPR18Long-term consequences of perinatal fatty acid amino hydrolase inhibition.Decoding functional metabolomics with docosahexaenoyl ethanolamide (DHEA) identifies novel bioactive signalsPotential anti-inflammatory actions of the elmiric (lipoamino) acids.Inhibition of human recombinant T-type calcium channels by the endocannabinoid N-arachidonoyl dopamine.Anandamide and diet: inclusion of dietary arachidonate and docosahexaenoate leads to increased brain levels of the corresponding N-acylethanolamines in piglets.Endocannabinoid binding to the cannabinoid receptors: what is known and what remains unknown.Anticonvulsant activity of N-palmitoylethanolamide, a putative endocannabinoid, in mice.Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell linesPsychopharmacology of the endocannabinoids: far beyond anandamide.A synaptogenic amide N-docosahexaenoylethanolamide promotes hippocampal development.N-arachidonyl-glycine modulates synaptic transmission in superficial dorsal hornMechanisms of exercise-induced hypoalgesia.N-Arachidonyl-glycine inhibits the glycine transporter, GLYT2a.Dietary docosahexaenoic acid supplementation alters select physiological endocannabinoid-system metabolites in brain and plasma.Identification of farnesyl pyrophosphate and N-arachidonylglycine as endogenous ligands for GPR92'Entourage' effects of N-palmitoylethanolamide and N-oleoylethanolamide on vasorelaxation to anandamide occur through TRPV1 receptors.The expanding field of cannabimimetic and related lipid mediators.N-Docosahexaenoylethanolamide promotes development of hippocampal neurons.Resolution of inflammation by N-arachidonoylglycine.N-Amino acid linoleoyl conjugates: anti-inflammatory activitiesCannabinoid receptors: nomenclature and pharmacological principlesSo what do we call GPR18 now?Further advances in the synthesis of endocannabinoid-related ligands.The therapeutic potential of drugs that target cannabinoid receptors or modulate the tissue levels or actions of endocannabinoids.Targeting the endocannabinoid system in treating brain disorders.
P2860
Q21093349-F9895C60-60AC-4B16-B6D7-2ED746CCD37CQ21202826-E58344F0-0209-4692-BB3D-2E9EA34FDBC9Q24541462-7C5FC8A4-918F-4D76-8928-935FDA236AA2Q24650559-2B5CD14C-5CC9-4FD4-B7AB-A8229B31000CQ24657799-1C0586C0-A9DB-454B-ADB5-D4CEB243FD87Q24671032-07D6D800-AA22-4E39-9838-027E2AE01D7BQ27009735-67C027B9-9783-4D33-B5EA-97EB0C2F047FQ27011679-47B29115-B148-4DC7-A190-B1BDC0274F41Q27496303-FFCF5790-9EF9-40F3-BCD6-BD3C5E256A3EQ27498684-D1E78A36-B336-4ADB-A6B5-39A568AA4951Q28236199-D5553E9E-0920-4501-A4EE-43E056A57E8CQ28238141-22FD9630-485E-4FED-B190-E28F887447A0Q28345246-6F16449A-F08E-43D9-8EB7-CEFC35B016E8Q28363051-B8F72F52-F444-4B2A-A463-438636F67C77Q28828513-1E62CCC1-1C3D-4662-96A2-BCD83F65035FQ30417555-7D7E9CF5-5748-4391-9FD6-C0E04F95C5C3Q30504292-97E10E3A-6BB1-4E56-BF5C-D2CB7EF804E0Q33279909-B1A5E0BB-BABF-4EEF-9F17-A14A40E93058Q33410345-4C0452DF-E591-4604-9271-824E1D8B673DQ33946795-255BE30A-C597-423F-BB50-EB3CECFFA7CAQ33997873-1C988991-2318-4F10-BDE4-1F67CFC24DB9Q34083248-69817D51-C273-4EFD-94F5-848FB36E623FQ34095006-D50B481F-B6D0-463B-AE9B-BD4040E641B1Q34190754-7E55F176-51D3-4246-9582-7CA195AFBC8CQ34205553-66A94DFC-516B-4629-B3BC-6C23E8E65384Q34356128-2C34B485-7D08-46EA-B5D6-6D5EB595629FQ34440671-6C6A6053-7E41-4B81-AB83-ADC01B5D19F9Q34555684-5A9725AC-A22B-4127-9D39-BE3F014C9842Q34559890-51814CE2-06E4-48EC-93AA-78B4B71D868CQ34781384-F9CE46F3-0F34-472B-AFBD-173A16F76489Q34807355-E2F38DE0-450C-4B74-8535-30A085DD5C35Q35048658-F06320B4-1F2B-4636-9082-3CB47D5CDC53Q35202551-5F9311CE-EBF0-48DD-AC2C-B297CBAD49C8Q35388701-8C06F7C2-9F87-49DB-BC82-C51F5AC101EEQ35672890-42BB63E9-B1E2-4C8B-BE4D-A9A938A2DD3EQ36044310-B7517B54-A074-4EA5-93B6-77F89012B8C1Q36176460-C21B6823-1EF2-4235-ACE5-A9ACE6E30060Q36341641-A39CC6FB-8D92-4BF0-8626-CADFDF2C9C3CQ36341688-D32CB7E1-D939-440A-AA4D-BDA3ADD05AEDQ36425999-4AA34E56-EB80-4A7B-8F24-E41BC675D574
P2860
Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor.
description
1997 nî lūn-bûn
@nan
1997 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Structural requirements for bi ...... he brain cannabinoid receptor.
@ast
Structural requirements for bi ...... he brain cannabinoid receptor.
@en
Structural requirements for bi ...... he brain cannabinoid receptor.
@nl
type
label
Structural requirements for bi ...... he brain cannabinoid receptor.
@ast
Structural requirements for bi ...... he brain cannabinoid receptor.
@en
Structural requirements for bi ...... he brain cannabinoid receptor.
@nl
prefLabel
Structural requirements for bi ...... he brain cannabinoid receptor.
@ast
Structural requirements for bi ...... he brain cannabinoid receptor.
@en
Structural requirements for bi ...... he brain cannabinoid receptor.
@nl
P2093
P921
P356
P1476
Structural requirements for bi ...... he brain cannabinoid receptor.
@en
P2093
P304
P356
10.1021/JM960752X
P407
P577
1997-02-01T00:00:00Z